Kidney Cancer Coverage From Every Angle
Advertisement
Advertisement

Recent News

Does Prior Antibiotic Use Affect Treatment Outcomes in Renal Cell Carcinoma?
Use of Pembrolizumab Before Radical Cystectomy in Urothelial Bladder Cancer
Early Study of Antibody-Drug Conjugate in Urothelial Cancer
Improved Quality of Life With Combination Immunotherapy in Advanced Kidney Cancer
ASCO 2018: Phase II Study Results With Erdafitinib in Metastatic Urothelial Cancer
FDA Restricts Use of Pembrolizumab or Atezolizumab in Some Patients Treated for Urothelial Carcinoma
Does Statin and Sartan Use Affect Outcomes in Patients Treated for Kidney Cancer?
ASCO 2018: ABACUS Investigates Atezolizumab Before Nephrectomy in Bladder Cancer
ASCO 2018: First-Line Pembrolizumab Monotherapy in Advanced Renal Cell Carcinoma
ASCO 2018: Is Adjuvant Therapy of Benefit in Children With Resected Kidney Cancer?
ASCO 2018: Can Some Patients With Metastatic Kidney Cancer Avoid Surgery With Sunitinib Alone?
AUA 2018: Risk Factors for pN1 Status in Surgically Treated Patients With Kidney Cancer
Predicting Outcomes in Renal Carcinoma Using EMT and Immune Signatures
FDA Alert: Efficacy Issues Identified in Trials of Pembrolizumab or Atezolizumab in Urothelial Cancer
AUA 2018: Effect of Cytoreductive Nephrectomy on Survival in Metastatic Non–Clear Cell Kidney Cancer
AUA 2018: Should Guidelines for Renal Cell Carcinoma Surveillance Be Revised?
Combination of Avelumab and Axitinib in First-Line Treatment of Clear Cell Kidney Cancer
Tivozanib After Sorafenib in Patients With Renal Cell Carcinoma
Simultaneous Administration of Chemotherapy and Checkpoint Inhibition in Metastatic Urothelial Cancer
FDA Grants Fast Track Designation to CB-839 in Combination With Cabozantinib for Advanced RCC
NCCN Annual Conference 2018: Debut of New Guidelines on Immunotherapy-Related Toxicity
FDA Approves Nivolumab/Ipilimumab Combination in Intermediate- or Poor-Risk RCC
Predicting Survival in Patients With Kidney Cancer: Do Sex Differences in Visceral Fat Matter?
FDA Grants Fast Track Designation to TAR-200 for the Treatment of Bladder Cancer
FDA Grants Breakthrough Therapy Designation to Enfortumab Vedotin for Advanced or Metastatic Urothelial Cancer
2018 Updates for NCCN Guidelines for Kidney Cancer
Survey Shows Higher Suicide Rate in Patients With Urologic Cancers
Preliminary Data on Immune Checkpoint Inhibitor in Urothelial Carcinoma
FDA Grants Breakthrough Therapy Designation to Erdafitinib for Metastatic Urothelial Cancer
Cardiovascular Biomarkers and Progression of Renal Cancer
Are Age and Sex Linked to Mortality After Adjuvant Therapy for Kidney Cancer?
Nivolumab Monotherapy in Metastatic Urothelial Carcinoma
GU Cancers Symposium: Cytoreductive Nephrectomy for Metastatic Papillary Kidney Cancer
GU Cancers Symposium: New Immunotherapy Combination in Advanced Kidney Cancer
GU Cancers Symposium: Can Gene Polymorphisms Predict Outcomes With Sunitinib in Kidney Cancer?
GU Cancers Symposium: Atezolizumab Versus Chemotherapy in IMvigor 211 Subgroup Analyses
GU Cancers Symposium: Crizotinib in Papillary Kidney Cancer With MET Alterations
GU Cancers Symposium: Novel Combination Therapies for Metastatic Kidney Cancer
GU Cancers Symposium: French Study of Nivolumab in 'Real-World' Metastatic Kidney Cancer Setting
GU Cancers Symposium: Predictive Biomarkers in Kidney Cancer
GU Cancers Symposium: Cabozantinib vs. Sunitinib in Untreated Patients With Advanced Kidney Cancer
GU Cancers Symposium: Pembrolizumab in Advanced Urothelial Cancer
GU Cancers Symposium: Atezolizumab Plus Bevacizumab in Advanced Kidney Cancer
ASCO-SITC 2018: Potential Biomarker of Response to Immunotherapy in Kidney Cancer
Early Study on Immunotherapy Agent for Advanced Renal Carcinoma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.